GF Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

GF Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.5K	Sell	11,043 -463	-4%	-$1.54K	﹤0.01%	412
2026 Q1	$35.3K	Buy	11,506 +1,402	+14%	+$5.42K	﹤0.01%	439
2025 Q4	$41.3K	Buy	10,104 +911	+10%	+$4.51K	﹤0.01%	421
2025 Q3	$44.9K	Sell	9,193 -582	-6%	-$3.06K	﹤0.01%	405
2025 Q2	$49.5K	Hold	9,775	–	–	﹤0.01%	415
2025 Q1	$51.7K	Buy	9,775 +1,759	+22%	+$12.8K	﹤0.01%	417
2024 Q4	$54.2K	Buy	+8,016	New	+$53.9K	﹤0.01%	384

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GF Fund Management's RXRX Position: Q2 2026 in Review

GF Fund Management reduced its Recursion Pharmaceuticals (RXRX) stake by 4% in Q2 2026, selling an estimated $1.54K and leaving 11,043 shares worth $40.5K. The position accounts for ﹤0.01% of the portfolio, ranked #412.

GF Fund Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $54.2K in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

GF Fund Management held 11,043 shares of Recursion Pharmaceuticals worth $40.5K as of Q2 2026.
GF Fund Management sold 463 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.54K.
Recursion Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #412 holding.
GF Fund Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Recursion Pharmaceuticals position peaked at $54.2K in Q4 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.